CHARITY COMMISSION FOR ENGLAND AND WALES Tru8tee8' Annual Report for the period From Ilt January 2022 To 3111 2022 Charfty name: Sallvary Gland Cane•r UK Charlty rng18trallon numbor. 1182762 Objectives and Activities Summary of th8 purp0888 of the charity as 8et out in it8 governing docwn8nt Parn 1.17 Help thom by raro Salivary gland cancer8. AthiocAt8 for the•e pthnt8 and caror8 by provKling p88r 8UPPOrt and information about théir di. ¢we arKI treatment. Promote arKI a8818t r88earch into all of salNary glarKI cancern, Ind11ng u3, diagno8, trgatments, arKI gJre8. To educate the wblic and healthcare communth'8s in all things related to salivary gland cancef8. induding raising awarene88 of 8ymrAoms. Summary of the main activiti8s in mlation to th08e purposés for the putAic benefrt, In particular, the a¢tMties, projects or servie identsfied in the accounts. Parn1.17 1.19 Supporting the communlty via In person and virtual rn88ting8 for patierrts. cArers and dinicians. Provhdlry Infomiation arKI Increasing awareness via leaflets, meetiW8, the website. 80cial mgdla and fundral8ing events. Ra181ng awarene88 of these cancers and trlr unmet need via Sp8a'ng, submitting materials and attending Expansion of the nthvork to support 811 salNary gland carKxr type8. ExpAnsion of tho charity's outputs to provide more re8earch and disease infomation. Statement confimiing whether the trustees have had regard to the guidarKe issued the Cha 1.18 The trustees have kept in mind tho tharity constilan arKI tre guidan from the Charities Commission in all of ts, actNities.
The event induded a presentsts'on on Carbon lon Therapy. what it is, how it works and how it relates to adenoid ¢ystic carcinoma and other salivary gland canc8rs. The e¥ent also induded updates from the 2022 ASCO corrference from Dr Melcaw and a fibwthllbeing session specrfically focussed on relax*'on and exercises for the leaffets, meeb'ngs, the Kebsite, social medm fvndrwsing events. tring the year we Contin to d8velop and expartd thè online presence of the charity. SGC is now engaged and acts've on all of the mainstream Social media platfomis, nduding our YouTub• ehannel. Content is posted frequently and con8iStently and the Board reVw& key actNty metrics regularly. 2022 8180 88w the launch of SCG'8 r vamped website following input from the pallent ¢ommunlty on content, functionalty and deswn. Regarding furKlraising. SGC hrt £23,025 in donation8 during 2022. Two key events were the Morrison family raisin9 over £10,000 at persona event in Glasgow. which wa8 featured In the Gla8gow Time8, and 8UPPOrter participats'on in the London Marathon rai8irvJ a similar fyurn. Raising awareness d thes8 cancers and thwr unmet n68d via sp88kn.ng and attendiffj ffleetings and Conferences. Dr Metcalf attended tho Amèrican Socth of Clinical Oncology {'ASCO') 2022 Conference. Three stud$ were presented an8ly8ing the effectlvene88 of various drug therapies. Dr Metcalf produced material8 and a vidao wesentthn outlinsng what was discussèd at ASCO. entitled 'lnnovations in Salivary Gland Cancer5. which he presented to and madg available to our Patnt )mmunty. SGC'S founder arKI Chair, Ms Kinloch, also esented at various events during the year induding at RareFest22 wthich was held in CamtKMlge. E¥p8nskin of the net to support all S81iv8ry cancer types. patients 8nd dinKian& at a Euro an level with EURACAN
Other
Funds hold as custodlan trustees on behalf of others Description of the assets Not applicable held in this capauty Name and objects ofthe eharity on whose behalf the assets are held and how this falls wrthin the custodian charity's objects Not aFWicable Details of arrangements for safe custC*Jy and segregation of such assets from the charity's own assets Not applicable Addltlonal Infomiatlon lopoonal) Nam•8 and addrM•M of advimrn lo1 Infornmtkn Typ• of N•m• Addr• advl••r Nam• of chhf •xecullv• or n•nM ol wilor staff m•mb•rn Iopuonal Inforniatlon) Exomptlon8 from dl8cIo8Urn Rea80n for nThli8do8ur• of k• nnel detai18 Other o tlonal Infomiatlon
'. tMAQNY (OMMtsYO I (4 I14*m1 APAJ ¥MII Rocolpt8 and payments accounts CC16• T• Oet?ils 1£
4AM4t8 forih• ¢harW• Lvlm use
Declarations Slgn•d b•half of th• ¢harity'• trustees Slgnaturn(8) Full nam8) PItIon l•g SKretary, Chalr, otc> Emma Jane Kinloch Shan8 Lisa Draper Chair Chief Financ4al Officer Dat• i&k 20U.
Nanws of th• eharfty truste88 WI manag• charlty Olllr• Ilt*ry} Mam• of pw•on {or body) ontStl•d int trusts• Ifan Emma Jane Kinloch Dr Robert Metcalf Olorunkemi Fausat Akanke Olaiya Shane Lisa Drapar Chalr The Board Trustee The Board The Board Chief FirAncial The Board 10 12 13 14 15 16 17 18 19 20 rate tru8te88- names of the director¥ at t8 date the Dl¥•¢tor nam• Name of tru8tee8 IldIng litkn Io Kyoperty b8k)ngiTrJ to the charity Trt•• nam•
Structure. Governanco and Management DesiptIon of thanty's Type of goveming doojment (trust deed. royal charter) p1.25 thanty is govemed by ts Constriulion. How 18 the d)arlty constituted? (e.g unincorporated association, CIO Trustee sèlection m8thc#ts including detai18 of any constituiional provisions e.g. eleth'on to post or name of any person or body entided to appoint one or more tru8teg8 p1.2$ rtrity is a CIO. Parn 125 TnJslee8 must ba appolntéd for a tem) of three year8 by a re3olution passed at operfy cer0d meeting of the charity en 8ele(air¥J trustee8, the charlty trustees have regard to the Skills, knowledge and experience needed for tha effective administration of the CIO. Addldonal Infomiatk•n (optlonal) You ma choose to indude further 8tatements vthere reknrrt abt Policie8 and procedures adopted for the induction and training of tru8tee8 P•• 1.51 The charity'8 organisational 8tructure and any wider netwo with which th¢ charrty work8 Pw• 1.51 Relationship wrth any related parti88 Pm1Jl Othar Reference and Admlnlstrafjve details Cha name Other name the cha ' Re istered cha number Charity's principal address Salrla GlarKI Cancer UK 1182762 Intemational House. 3e*38 Comhill, Lolon EC3V 3NG
Financial Reviow Review of the ¢harty's financial position at the end of the perlod P4r8 f 21 As at 31° D8rnber 2022 the charty held cash balan of £48.096, {prior year £39,922) the result of £8,174 in net receipts for the year (prior year £13,314). The Charity received income of £23,025 (prior year £27,832), the majority being donations through various sourc88 including donation platfomis and personal legacies, together with other income received from collaboration8 Wrth other organi8ation8 and specthc fund raising events. The chanty's financial position will allow sufficnt funding to support the initiative8 planned for 2023, including any grant activity. Statement explaining tha policy for holding reserves 8tating why they are held P•r• 1.22 The cash balance Is held In order to support the overall objectlves of the chanty. Cash 18 used to cover operating expen8e8, develop the ch8rity'8 presence through marketing and fund Specffic patlenU¢linician events. Cash hold 18 a180 the source funds of any grant opportunitie8 a8 they ari88. Amount of m8erve8 held Rea8on8 for holding zero re88rve8 Details of fund materially In deflclt Explanation of any uncertaint188 about the charity continuing a8 a going concem ParA 1.22 P•r• 1.22 £48 096 in ca8h. Not applica8 Para 1.24 Not appllcable P•M 1.23 There are no un¢ertalntle8 around the charty's ability to continue a8 a going ncern. Addltlonal Infomiatlon loptlonal) You ma choo88 to Include further 8tatements where relevant about.. The charity's principal 80urces of funds (inciudlng any fundraising) P•r• 1.47 Investment policy and objectives including any social investment polioy adopted M 1.46 A description of the principal risks facing the charty Para 1.48
we have been part of the team that developed the ESMO Guidelines for rare Salivary Gland Canr8, and the STARTER registry, a clinical r8gi8try for rare adult solid Canrs. Both projects have provided an opportunity for European4yide collaboration and network building across all cancer typ8S. Th8 ESMO Salivary Gland Cancer Guidelines for diagnosls, treatment and follow-up are now available on our yb$Ite. Expansion of the chanty's othputs to pmvide moTr research and disease The genomlcJ educational material tho charty comm8nced work on in 2021, in collaboration with Roche, was finalised and publi6hed in 2022. The genomics leafi8t highlights the benefits of tumour profiling to develop new, better and more targeted treatment8. Th8 material wlll infom patients and also assist them in how to donate tumours to the nats'onal salNary gland cancer research programme at The Christie cancer ntro. We continued to produce our vlds>O 88rl68, releaslng recordlng8 of the presentations at our hybrid meetings to ensure we reach as many people a8 PO88iblè. Vve al80 continued to add patient 8torie$ on Social media and on our web8ite. Addltlon•l Inforniatlon loptlon•l You ma cho¢)80 to include further Statements where relevant abouL' Achi8vement8 against objactiv98 8Ot Para 1.41 Perfomiance of fundraising activiti'e8 against objective8 8et Pwa 1,41 Investment perfonnance against objectives P•r• 1.41 Other
Commission on publlc are regulady reviewed at Trustse meetings. Th8 charity's aims. are regularly published via our social media outlets and are the foundation for all activities and decisions within the charity. Th8 trustees ensure the prioriti8ation of activities is ned with these aim8. Additional InfomMtlon loptional) You ma choose to include further statement8 where relevant about.. 1.38 In 2022 we finalised our policy on grant making ahead of putting (Krt our first call in 2023. Policy on grant making Parn 1.38 Policy on social inv08tment Includlng program related inv8Stment 1.38 Once again we am hugaly grateful for the 8UPPOrt we received from our volunteers 888i8ting us in 8pecffic projects and outputs, sharing their gtorie8 and social media channels, and 'on the day, phy8ical 8UPPOrt at our events. Contributlon mad8 by volunteers Other Achlevemonts and PorfonnanGe SORP r•hr•re• Supporting the communrty via fft person and virtual m88tings forpatsants, ¢arers and clinanS. Summary of the main achievements of the charity, identifying the dlfference the charty's work has made to the circumstances of its beneficiaries and any Wer benefrts to society as a whole. P•M120 For our hybrid lin per80nlvirtual) meetings during 2022. we were able to provide bursariè8 for pat'ents and their carers to support their in-person att8ndance when needed. The hybrid structure of our events has facilitated strong attendancè from our communty across the country and intemationally. continued to provlde regular communi¢ion and newsletterB to the network. Our Junè 2022 meetlng was held in London.